Comera Life Sciences Holdings, Inc. announced a partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture one of Comera's lead SQore(TM) excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company. Comera is helping companies transform their intravenously administered (IV) biologics into patient delivered subcutaneous (SQ) formulations using a validated and de-risked approach that dramatically reduces time to clinic and commercialization. Comera's proprietary SQore platform integrates computational modeling, a robust library of excipients, and advanced formulation engineering to expedite the development of patient-preferred biotherapeutic formulations, while fostering novel intellectual property creation.